Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 501–600 of 1,031
Recommendations for Cell-Free DNA Assay Validations
Lockwood, C. M., Borsu, L., Cankovic, M., Earle, J. S. L., Gocke, C. D., Hameed, M., Jordan, D., Lopategui, J. R., Pullambhatla, M., Reuther, J., et al. (2023) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.09.004 · Cited by 96
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects
Daly, A., Yuan, B., Fina, F., Caberg, J., Trivellin, G., Rostomyan, L., de Herder, W. W., Naves, L. A., Metzger, D. L., Cuny, T., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0082 · Cited by 101
Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing
Rana, H. Q., Gelman, R., LaDuca, H., McFarland, R., Dalton, E., Thompson, J., Speare, V., Dolinsky, J. S., Chao, E. C., & Garber, J. E. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy001 · Cited by 93
Danielsson, M., Halvardson, J., Davies, H., Torabi Moghadam, B., Mattisson, J., Rychlicka-Buniowska, E., Jaszczyński, J., Heintz, J., Lannfelt, L., Giedraitis, V., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0533-z · Cited by 97
Discovering the drivers of clonal hematopoiesis
Pich, O., Reyes-Salazar, I., Gonzalez-Perez, A., & Lopez-Bigas, N. (2022) · Nature Communications · doi:10.1038/s41467-022-31878-0 · Cited by 96
“SD H AF 2 AB L2 LZ TR 1 AT E1 CGC Myeloid CH Metastasis (26) Primary (23)”
BackgroundClonal Hematopoiesis and Risk of Incident Lung Cancer
Tian, R., Wiley, B. J., Liu, J., Zong, X., Truong, B. M. T., Zhao, S., Uddin, M. M., Niroula, A., Miller, C. A., Mukherjee, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00857 · Cited by 105
Lin, A. E., Bapat, A. C., Xiao, L., Niroula, A., Ye, J., Wong, W. J., Agrawal, M., Farady, C. J., Boettcher, A., Hergott, C. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065597 · Cited by 107
TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells
Rasmussen, K. D., Berest, I., Keβler, S., Nishimura, K., Simón-Carrasco, L., Vassiliou, G. S., Pedersen, M. T., Christensen, J., Zaugg, J. B., & Helin, K. (2019) · Genome Research · doi:10.1101/gr.239277.118 · Cited by 95
Malcovati, L., & Cazzola, M. (2015) · Hematology · doi:10.1182/asheducation-2015.1.299 · Cited by 105
Premature Aging in Young Cancer Survivors
Armenian, S. H., Gibson, C. J., Rockne, R. C., & Ness, K. K. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy229 · Cited by 92
The cell of origin and the leukemia stem cell in acute myeloid leukemia
Chopra, M., & Bohlander, S. K. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22805 · Cited by 115
SanMiguel, J. M., Eudy, E., Loberg, M. A., Young, K. A., Mistry, J. J., Mujica, K. D., Schwartz, L. S., Stearns, T. M., Challen, G. A., & Trowbridge, J. J. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0086 · Cited by 97
Genomics of chronic neutrophilic leukemia
Maxson, J. E., & Tyner, J. W. (2016) · Blood · doi:10.1182/blood-2016-10-695981 · Cited by 99
McClatchy, J., Strogantsev, R., Wolfe, E., Lin, H. Y., Mohammadhosseini, M., Davis, B. A., Eden, C., Goldman, D., Fleming, W. H., Conley, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43697-y · Cited by 95
Chen, X., & Wood, B. L. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.006 · Cited by 99
Severson, E. A., Riedlinger, G., Connelly, C. F., Vergilio, J., Goldfinger, M., Ramkissoon, S. H., Frampton, G. M., Ross, J. S., Fratella-Calabrese, A., Gay, L. M., et al. (2018) · Blood · doi:10.1182/blood-2018-03-840629 · Cited by 99
Batalini, F., Peacock, E. G., Stobie, L., Robertson, A., Garber, J. E., Weitzel, J. N., & Tung, N. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1193-1 · Cited by 104
Gurnari, C., Pagliuca, S., Prata, P. H., Galimard, J., Catto, L. F. B., Larcher, L., Sébert, M., Allain, V., Patel, B. J., Durmaz, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00710 · Cited by 103
“001) and clonal burdens (median variant allele frequency 20% [IQR 5-27] v 30% [19-44]; P 5 .”
BackgroundResultClinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Bono, E. B., McLornan, D. P., Travaglino, E., Gandhi, S., Gallì, A., Khan, A. A., Kulasekararaj, A. G., Boveri, E., Raj, K. K., Elena, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0457-1 · Cited by 98
Unidirectional association of clonal hematopoiesis with atherosclerosis development
Díez-Díez, M., Ramos-Neble, B. L., de la Barrera, J., Silla-Castro, J. C., Quintas, A., Vázquez, E., Rey-Martín, M. A., Izzi, B., Sánchez-García, L., García‐Lunar, I., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03213-1 · Cited by 105
Siudeja, K., Nassari, S., Gervais, L., Skorski, P., Lameiras, S., Stolfa, D., Zande, M., Bernard, V., Frio, T. R., & Bardin, A. J. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.09.016 · Cited by 93
Identification of cell-type-specific mutations in nodal t-cell lymphomas
Nguyen, T. B., Sakata-Yanagimoto, M., Asabe, Y., Matsubara, D., Kano, J., Yoshida, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2016.122 · Cited by 93
Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis
Liu, W., Yalcinkaya, M., Maestre, I. F., Olszewska, M., Ampomah, P. B., Heimlich, J. B., Wang, R., Vela, P. S., Xiao, T., Bick, A. G., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00281-3 · Cited by 93
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans
Kaasinen, E., Kuismin, O., Rajamäki, K., Ristolainen, H., Aavikko, M., Kondelin, J., Saarinen, S., Berta, D. G., Katainen, R., Hirvonen, E. A. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09198-7 · Cited by 92
Tocchetti, C. G., Ameri, P., de Boer, R. A., D’Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D. K., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa222 · Cited by 100
Haring, B., Reiner, A. P., Liu, J., Tobias, D. K., Whitsel, E., Berger, J. S., Desai, P., Wassertheil‐Smoller, S., LaMonte, M. J., Hayden, K. M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018789 · Cited by 91
Lauer, E. M., Mutter, J., & Scherer, F. (2022) · Leukemia · doi:10.1038/s41375-022-01618-w · Cited by 110
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Welch, C. L., Aldred, M. A., Balachandar, S., Dooijes, D., Eichstaedt, C. A., Gräf, S., Houweling, A. C., Machado, R. D., Pandya, D., Prapa, M., et al. (2023) · Genetics in Medicine · doi:10.1016/j.gim.2023.100925 · Cited by 98
Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation
Gondek, L. P., Zheng, G., Ghiaur, G., DeZern, A. E., Matsui, W., Yegnasubramanian, S., Lin, M.-T., Levis, M., Eshleman, J. R., Varadhan, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.63 · Cited by 89
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias
Gibson, C. J., Kennedy, J. A., Nikiforow, S., Kuo, F. C., Alyea, E. P., Ho, V., Ritz, J., Soiffer, R., Antin, J. H., & Lindsley, R. C. (2017) · Blood · doi:10.1182/blood-2017-01-764951 · Cited by 82
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 97
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease
Dawoud, A. A. Z., Gilbert, R. D., Tapper, W. J., & Cross, N. C. P. (2022) · Leukemia · doi:10.1038/s41375-021-01382-3 · Cited by 92
Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Vlasschaert, C., Robinson‐Cohen, C., Chen, J., Akwo, E. A., Parker, A., Silver, S. A., Bhatraju, P. K., Poisner, H. M., Cao, S., Jiang, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02854-6 · Cited by 112
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 98
Leukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 102
CHIP, ICUS, CCUS and other four-letter words
Bejar, R. L. (2017) · Leukemia · doi:10.1038/leu.2017.181 · Cited by 98
Babushok, D. V., Duke, J. L., Xie, H. M., Stanley, N. L., Atienza, J., Perdigones, N., Nicholas, P., Ferriola, D., Li, Y., Huang, H., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010918 · Cited by 93
“We speculate that differences in clonal manifestations of patients with pediatric- and adult-onset aAA are related to the higher prevalence of subclinical age-associated mutations in adults.(55-58) In pediatric population, where age-related mutations are rare, PIGA and HLA loss are the primary mechanisms of early bone…”
BackgroundKon, A., Yamazaki, S., Nannya, Y., Kataoka, K., Ota, Y., Nakagawa, M. M., Yoshida, K., Shiozawa, Y., Morita, M., Yoshizato, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-762393 · Cited by 95
Clinical implications of recurrent gene mutations in acute myeloid leukemia
Yu, J., Li, Y., Zhang, D., Wan, D., & Jiang, Z. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00161-7 · Cited by 102
Azacytidine Treatment for VEXAS Syndrome
Raaijmakers, M. H. G. P., Hermans, M., Aalbers, A., Rijken, M., Dalm, V. A. S. H., van Daele, P., & Valk, P. J. M. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000661 · Cited by 91
Nakao, T., Bick, A. G., Taub, M. A., Zekavat, S. M., Uddin, M. M., Niroula, A., Carty, C. L., Lane, J., Honigberg, M. C., Weinstock, J. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl6579 · Cited by 94
Cobo, I., Tanaka, T. N., Glass, C. K., & Yeang, C. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000688 · Cited by 95
Sleep exerts lasting effects on hematopoietic stem cell function and diversity
McAlpine, C. S., Kiss, M. G., Zuraikat, F. M., Cheek, D. M., Schiroli, G., Amatullah, H., Huynh, P., Bhatti, M. Z., Wong, L. P., Yates, A. G., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220081 · Cited by 98
“Clonally expanded HSPCs often harbor mutations in epigenetic modifiers, and CH is strongly associated with epigenetic age acceleration (Genovese et al., 2014; Nachun et al., 2021).”
BackgroundClonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis
Arends, C. M., Weiss, M., Christen, F., Eulenberg-Gustavus, C., Rousselle, A., Kettritz, R., Eckardt, K.-U., Chan, W., Hoyer, K., Frick, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223305 · Cited by 86
“Clonal hematopoiesis of indeterminate potential (CHIP) – defined by the presence of a somatic hematologic cancer-associated gene mutation with a variant allele frequency of ≥2% – occurs in the peripheral blood of at least 10% of individuals older than 60 years of age without any history of a hematologic disorder.(1,2)…”
BackgroundWhen Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
Rodríguez, J. K., Ávila, J., Rolfo, C. D., Ruíz-Patiño, A., Russo, A., Ricaurte, L., Ordóñez‐Reyes, C., Arrieta, O. G., Zatarain-Barrón, Z. L., Recondo, G., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00144-6 · Cited by 98
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Yoo, H. Y., Kim, N., Kim, W. S., Lee, S., Kim, S., Kang, S. Y., Jang, H.-Y., Lee, J. E., Kim, J., Kim, S. J., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139253 · Cited by 94
Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2344 · Cited by 92
“Population 104 based screens revealed clonal hematopoiesis in about 10% of healthy persons older than 65 years and 105 found it to be associated with an approximately 10-fold increased risk for hematologic cancers (8,9).”
BackgroundChen, Z., Amro, E. M., Becker, F., Hölzer, M., Rasa, S. M. M., Njeru, S. N., Han, B., Di Sanzo, S., Chen, Y., Tang, D., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181505 · Cited by 86
“, 2011), and an increase in the selection of clones that carry recurrent mutations (predominantly in genes that regulate epigenetic modification and gene expression; Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014).”
BackgroundGarcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
“5 (9-639) Median white blood cell count (range), 310(9)/L 2.”
Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD
Khetarpal, S. A., Qamar, A., Bick, A. G., Fuster, J. J., Kathiresan, S., Jaiswal, S., & Natarajan, P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.05.045 · Cited by 84
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 108
GWAS of mosaic loss of chromosome Y highlights genetic effects on blood cell differentiation
Terao, C., Momozawa, Y., Ishigaki, K., Kawakami, E., Akiyama, M., Loh, P., Genovese, G., Sugishita, H., Ohta, T., Hirata, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12705-5 · Cited by 98
Self-citationA six-attribute classification of geneticmosaicism
Martínez‐Glez, V., Tenorio, J. A., Nevado, J., Gordo, G., Rodríguez‐Laguna, L., Feito, M., de Lucas, R., Jurado, L. A. P., Ruiz‐Pérez, V. L., Torrelo, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0877-3 · Cited by 98
“Similarly, pathogenic mosaic variants of TET2, ASXL1, and DNMT3A are associated with hematologic cancers.(127,128) Finally, there are also several chromosomal syndromes that are only seen in a mosaic form, including Pallister–Killian syndrome and trisomies for several distinct chromosomes, such as 8, 9, and 14 ref.”
BackgroundPrevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
van Zeventer, I. A., Salzbrunn, J. B., de Graaf, A. O., van der Reijden, B. A., Boezen, H. M., Vonk, J. M., van der Harst, P., Schuringa, J. J., Jansen, J. H., & Huls, G. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004062 · Cited by 83
“Whole-exome sequencing has revealed CH to be virtually absent in individuals younger than 30 years of age, while being present in 20% to 30% of individuals aged 50 to 60 years.(1,2) By using a more sensitive sequencing technique, small clones were shown to be almost”
BackgroundMethodShah, Y., Priore, S. F., Li, Y., Tang, C. N., Nicholas, P., Kurre, P., Olson, T. S., & Babushok, D. V. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004201 · Cited by 92
Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review
Sario, G. D., Rossella, V., Famulari, E. S., Maurizio, A., Lazarević, D., Giannese, F., & Felici, C. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1152470 · Cited by 94
“Moreover, recent reports of somatic mutations accumulating both in solid tissues and in the hematopoietic system as a function of age are reported (Genovese et al., 2014; Alexandrov et al., 2015).”
BackgroundGenetic modification of inflammation- and clonal hematopoiesis–associated cardiovascular risk
Yu, Z., Fidler, T. P., Ruan, Y., Vlasschaert, C., Nakao, T., Uddin, M. M., Mack, T., Niroula, A., Heimlich, J. B., Zekavat, S. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168597 · Cited by 83
“CHIP is associated with an increased risk of hematologic malignancy and all-cause mortality (3, 4), as well as a range of cardiovascular diseases (CVDs) (6–10).”
BackgroundNormal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration
Olson, O. C., Kang, Y.-A., & Passegué, E. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035519 · Cited by 76
Yura, Y., Miura-Yura, E., Katanasaka, Y., Min, K.-D., Chavkin, N., Polizio, A. H., Ogawa, H., Horitani, K., Doviak, H., Evans, M. A., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.319314 · Cited by 87
“1 cells in the presence or absence of the genotoxic agent doxorubicin under the following conditions: (1) untreated cells (nonmodified), (2) lentivirus/Cas9/ sgRNA that does not target a DNA locus (nontargeted), (3) lentivirus/Cas9/sgRNA treatment that targets an intron of the Actb gene (noncoding; Figure VI in the Da…”
BackgroundSomatic clonal evolution: A selection-centric perspective
Scott, J. G., & Marusyk, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.006 · Cited by 92
Turning the tide in myelodysplastic/myeloproliferative neoplasms
Deininger, M. W., Tyner, J. W., & Solary, É. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.40 · Cited by 96
Shin, J. J., Schröder, M., Caiado, F., Wyman, S. K., Bray, N., Bordi, M., DeWitt, M. A., Vu, J. T., Kim, W., Hockemeyer, D. F., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108093 · Cited by 95
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
Sun, Q.-Y., Ding, L.-W., Tan, K.-T., Chien, W., Mayakonda, A., Lin, D.-C., Loh, X.-Y., Xiao, J.-F., Meggendorfer, M., Alpermann, T., et al. (2017) · Leukemia · doi:10.1038/leu.2016.160 · Cited by 86
Aging of hematopoietic stem cells: DNA damage and mutations?
Moehrle, B., & Geiger, H. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.06.253 · Cited by 93
“Comet assay experiments in aged HSCs revealed a twofold increase in DNA damage level in steady state [50,61] Mutation frequency in human and murine BM is increased twofold upon aging [26,61,64,65] Incidence of leukemia increases dramatically upon aging [77,79,80]”
Managing Clonal Hematopoiesis in Patients With Solid Tumors
Bolton, K. L., Gillis, N. K., Coombs, C. C., Takahashi, K., Zehir, A., Bejar, R., Garcia-Manero, G., Futreal, A., Jensen, B. C., Diaz, L. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00331 · Cited by 87
Busque, L., Sun, M., Buscarlet, M., Ayachi, S., Feroz Zada, Y., Provost, S., Bourgoin, V., Mollica, L., Meisel, M., Hinterleitner, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000770 · Cited by 87
“60 years old and confers an increased risk of progression to hematological cancers and cardiovascular diseases.(5,6,8,9) The precise risk associated with the presence of CH in healthy individuals is uncertain; hence, the creation of a clinical entity named clonal hematopoiesis of indeterminate potential (CHIP).”
BackgroundTelomerase abrogates aneuploidy‐induced telomere replication stress, senescence and cell depletion
Meena, J. K., Cerutti, A., Beichler, C., Morita, Y., Bruhn, C., Kumar, M., Kraus, J. M., Speicher, M. R., Wang, Z., Kestler, H. A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490070 · Cited by 87
“…interest given that stem and progenitor cells were identified as the cell type of origin of cancer formation in cancer mouse models and cancer patients (Alcantara Llaguno et al , 2009; Barker et al , 2009; Jan et al , 2012; Welch et al , 2012; Genovese et al , 2014; Jaiswal et al , 2014).”
Hu, Y., Alden, R. S., Odegaard, J. I., Fairclough, S. R., Chen, R., Heng, J., Feeney, N., Nagy, R. J., Shah, J., Ulrich, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1745 · Cited by 86
Sano, S., Wang, Y., Ogawa, H., Horitani, K., Sano, M., Polizio, A. H., Kour, A., Yura, Y., Doviak, H., & Walsh, K. (2021) · JCI Insight · doi:10.1172/jci.insight.146076 · Cited by 79
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
“Most of the mutations were identified in genes encoding for known leukemia drivers such as the chromatin modifiers TET2, ASXL1, and DNMT3A (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Shlush et al., 2014; McKerrell et al., 2015; Young et al., 2016; Buscarlet et al., 2017).”
BackgroundSelfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes
Maher, G. J., Ralph, H. K., Ding, Z., Koelling, N., Mlcochova, H., Giannoulatou, E., Dhami, P., Paul, D. S., Stricker, S. H., Beck, S., et al. (2018) · Genome Research · doi:10.1101/gr.239186.118 · Cited by 85
“%) of clonal mutations are prevalent and their incidence and frequency increase with age (Hafner et al. 2010; Laurie et al. 2012; Genovese et al. 2014; Jaiswal et al. 2014; Martincorena et al. 2015; McKerrell et al. 2015; Acuna-Hidalgo et al. 2017; Coombs et al. 2017; Martincorena et al. 2017; Zink…”
BackgroundPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
Ok, C. Y., Loghavi, S., Sui, D., Wei, P., Kanagal‐Shamanna, R., Yin, C. C., Zuo, Z., Routbort, M. J., Tang, G., Tang, Z., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191148 · Cited by 86
Metabolism as master of hematopoietic stem cell fate
Ito, K., Bonora, M., & Ito, K. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2534-z · Cited by 90
Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., Adelman, C. A., Qiu, P., Easter, A., Dearden, S. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0931 · Cited by 96
Cole, C. B., Russler-Germain, D. A., Ketkar, S., Verdoni, A. M., Smith, A. M., Bangert, C. V., Helton, N. M., Guo, M., Klco, J. M., O’Laughlin, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93041 · Cited by 84
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
Höllein, A., Meggendorfer, M., Dicker, F., Jeromin, S., Nadarajah, N., Kern, W., Haferlach, C., & Haferlach, T. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018023432 · Cited by 89
“OS following relapse at 24 months 48% [95% Cl, 12-77] vs 54% [14-83] (n.”
Enabling Precision Oncology Through Precision Diagnostics
Brown, N. A., & Elenitoba‐Johnson, K. S. J. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012735 · Cited by 93
When Genome Maintenance Goes Badly Awry
Kass, E. M., Moynahan, M. E., & Jasin, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.021 · Cited by 89
“It is important to note, however, that the presence of microhomology at breakpoint junctions does not definitively distinguish whether a junction arises from MMEJ: canonical NHEJ will join DNA ends with long 50 overhangs to give rise to junctional microhomology (Ghezraoui et al., 2014).”
Ommen, H. B. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715614529 · Cited by 91
“The DNMT3A mutation in the described case is probably a marker of monoclonal hematopoiesis of unknown significance, as recently described [Jaiswal et al. 2014; Genovese et al. 2014].”
BackgroundThe 2016 revision to the World Health Organization classification of myelodysplastic syndromes
Hong, M., & He, G. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0002 · Cited by 83
“8 × 109/L,[7] the WHO thresholds defining cytopenia still remain as in the original IPSS: hemoglobin <10g/dL, platelets <100× 109/L, absolute neutrophil count <1.”
Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., et al. (2021) · Leukemia · doi:10.1038/s41375-020-0917-7 · Cited by 79
Germline risk of clonal haematopoiesis
Silver, A. J., Bick, A. G., & Savona, M. R. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00356-6 · Cited by 82
Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
Hernández-Malmierca, P., Vonficht, D., Schnell, A., Uckelmann, H. J., Bollhagen, A., Mahmoud, M. A. A., Landua, S.-L., van der Salm, E., Trautmann, C. L., Raffel, S., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.007 · Cited by 86
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population
van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.006 · Cited by 91
High-throughput sequencing for noninvasive disease detection in hematologic malignancies
Scherer, F., Kurtz, D. M., Diehn, M., & Alizadeh, A. A. (2017) · Blood · doi:10.1182/blood-2017-03-735639 · Cited by 90
“Noninvasive disease detection in myeloid malignancies Acute myeloid leukemia and myelodysplastic syndrome Over the past 5 years, systematic genetic profiling of PB cells in healthy individuals byHTS-basedmethods has led to a growing understanding of potential precancerous conditions in hematologic cancers.138-142 Seve…”
BackgroundHusby, S., Favero, F., Nielsen, C., Sørensen, B. S., Bæch, J., Grell, K., Hansen, J. W., Rodríguez-González, F. G., Haastrup, E. K., Fischer‐Nielsen, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0795-z · Cited by 87
Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk
Tobias, D. K., Manning, A. K., Wessel, J., Raghavan, S., Westerman, K. E., Bick, A. G., DICORPO, D. A., Whitsel, E. A., Collins, J. M., Correa, A., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0805 · Cited by 90
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“The data from this study are instrumental for the further understanding of the biology of AML in the aging population, one of the main challenges that we are now facing.(141)”
MethodHuang, Y., Chen, C.-W., Sundaramurthy, V., Slabicki, M. M., Hao, D., Watson, C. J., Tovy, A., Reyes, J. M., Dakhova, O., Crovetti, B. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0560 · Cited by 86
“The variants were compiled from reports of mutations in CH (1, 2, 25), cancer, and TBRS (17, 18) and cover a large portion of reported mutations.”
BackgroundHematopoietic stem cell aging and leukemia transformation
Díaz, P. A. C., Mistry, J. J., & Trowbridge, J. J. (2023) · Blood · doi:10.1182/blood.2022017933 · Cited by 87
Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities
Tétreault, M., Bareke, E., Nadaf, J., Alirezaie, N., & Majewski, J. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1039516 · Cited by 92
“reported somatic mutations in hematologic cancer genes in 10% of individuals above the age of 65 [71].”
BackgroundMutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Quek, L. S., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., Garnett, C., Jeffries, S., Walter, C. U., Piechocki, K., Timbs, A., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000760 · Cited by 87
RUNX1 Mutations in Inherited and Sporadic Leukemia
Bellissimo, D. C., & Speck, N. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00111 · Cited by 84
“The presence of CHIP is detected by an increase in the fraction of a mutated allele in peripheral blood (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014; McKerrell et al., 2015).”
BackgroundInfluentialBoettcher, S., Wilk, C. M., Singer, J., Beier, F., Burcklen, E., Beisel, C., Ventura Ferreira, M. S., Gourri, E., Gassner, C., Frey, B. M., et al. (2020) · Blood · doi:10.1182/blood.2019003079 · Cited by 81
The duality of human oncoproteins: drivers of cancer and congenital disorders
Castel, P., Rauen, K. A., & McCormick, F. P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0256-z · Cited by 83
Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches
Zhang, L., Mack, R. M., Breslin, P., & Zhang, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00994-z · Cited by 89
Molecular mechanisms underlying lineage bias in aging hematopoiesis
Elias, H. K., Bryder, D., & Park, C. Y. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.11.002 · Cited by 83
Epigenomic drivers of immune dysfunction in aging
Keenan, C. R., & Allan, R. S. (2019) · Aging Cell · doi:10.1111/acel.12878 · Cited by 76
“…appears to reduce with age with an exponential increase in the occurrence of clonal hematopoiesis, where one mutant HSC produces an overwhelming proportion of mature blood cells, especially after the age of 45–60 in humans (Genovese et al., 2014; Jaiswal et al., 2014; McKerrell & Vassiliou, 2015).”
BackgroundClonal hematopoiesis and inflammation – the perpetual cycle
Avagyan, S., & Zon, L. I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.12.001 · Cited by 79
Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia
Bloom, M., Maciaszek, J. L., Clark, M. E., Pui, C., & Nichols, K. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2020.1685866 · Cited by 89
“Indeed, somatic mutations associated with clonal hematopoiesis of indeterminate potential (CHIP) can persist in the blood even during remission [166,167].”
Background
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.